Folate Modulation of Endothelial Nitric Oxide Synthase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for cardiovascular diseases like atherosclerosis, particularly those targeting oxidative stress, have been disappointing due to a lack of clear understanding in redox signaling and the inefficacy of simple antioxidants in improving NO bioavailability and endothelial function.
Innovation Solution
The use of folates, specifically 5-methyltetrahydrofolate, which directly modulates endothelial nitric oxide synthase (eNOS) by scavenging reactive oxygen species, increasing the vascular BH4/total biopterin ratio, and reversing eNOS uncoupling, thereby enhancing NO-mediated endothelial function and reducing vascular superoxide production without the need for additional active agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If simple antioxidants are used to target oxidative stress in cardiovascular diseases, then ROS scavenging is achieved, but therapeutic outcome is disappointing due to inability to improve NO bioavailability and endothelial function
Solution Approach 1:
The patent changes the chemical parameter of the antioxidant from simple antioxidants to polyphenolic compounds with specific structural characteristics (multiple phenolic hydroxyl groups in specific arrangements). This parameter change enables the compounds to simultaneously scavenge ROS and protect eNOS function, thereby improving therapeutic outcome while addressing oxidative stress
Solution Approach 2:
The patent introduces polyphenolic compounds as intermediary substances that mediate between ROS and eNOS. These compounds act as ROS scavengers while also preventing eNOS uncoupling, thus serving as a bridge that connects ROS management with endothelial function improvement, resolving the contradiction between antioxidant action and therapeutic efficacy
2Object-generated harmful factors
If eNOS uncoupling occurs due to ROS oxidation of BH4, then superoxide production increases, but NO production decreases leading to vascular dysfunction
Solution Approach 1:
The patent converts the harmful effect of eNOS uncoupling into a beneficial outcome by using polyphenolic compounds that prevent uncoupling in the first place. These compounds scavenge ROS that would otherwise oxidize BH4, thereby preventing superoxide production and maintaining NO production. The harm of oxidative stress is converted into benefit through protective antioxidant action
Solution Approach 2:
The patent changes the redox state parameter of the eNOS system by introducing polyphenolic compounds that maintain BH4 in its reduced, functional state. This parameter change prevents the transition from coupled to uncoupled eNOS, thereby maintaining the balance between superoxide and NO production in favor of NO
3Quantity of substance
If folates are used to lower plasma total homocysteine levels, then cardiovascular risk markers improve, but clinical outcome in larger trials does not improve
Solution Approach 1:
The patent changes the chemical structure parameter of folate to polyphenolic compounds, which have different mechanisms of action. Instead of merely lowering homocysteine levels through folate metabolism, polyphenolic compounds directly protect eNOS function and scavenge ROS, providing a different therapeutic parameter that translates to improved clinical outcomes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Folates effectively improve NO-mediated endothelial-dependent vasomotor responses and reduce vascular superoxide production, demonstrating specific antioxidant effects in atherosclerosis, achieving therapeutic benefits by directly enhancing eNOS activity and reversing uncoupling.
Implementation Method 1
Folates...scavenging reactive oxygen species (ROS), such as peroxynitrite
Implementation Method 2
increasing vascular BH4 and the BH4/total biopterin ratio
Implementation Method 3
The nitric oxide synthases (NOS) are a group of enzymes (EC 1.14.13.39) responsible for the synthesis of NO from the terminal nitrogen atom of L-arginine
Implementation Method 4
direct enhancing eNOS activity
Implementation Method 5
reducing vascular superoxide
Data Source
AI summary
This invention relates to the use of folates for the prevention and/or treatment of cardiovascular diseases, such as atherosclerosis, and in particular for modulating endothelial nitric oxide synthase (eNOS). The invention further relates to pharmaceutical preparations consisting of said folates and a pharmaceutically acceptable carrier, optionally in combination with other pharmaceutically active agents, as well as therapeutic methods using said folates or pharmaceutical preparations thereof.